Search

Pancreatic carcinoma incidence showed a significant increase in men over the last few years and the prognosis remains poor. Patients are treated with different pharmacological plans with no evidence about gender-specific adverse effects. We aimed to investigate differences in the incidence of chemotherapy side effects in the treatment of pancreatic cancer, to provide insights toward a personalized assistance based in individual needs. The sample population is composed of 207 patients. Regression model highlighted the predictive role of female gender for alopecia, constipation, hand- foot syndrome, and epigastric pain. Also, considering single therapeutic schemes, gender differences have been reported. Moreover, evaluating the effect of age, a general reduced risk of toxicity has been reported in younger patients. To personalize chemotherapy and increase patient survival rate and life quality during the therapy, gender medicine and pharmacology studies are recommended. Key words: gender differences, adverse effects, drugs toxicity, chemotherapy, pancreatic carcinoma. La frequence du cancer du pancreas chez l'homme a decrit une courbe nettement ascendante au cours des dernieres annees et le pronostic demeure defavorable. Les patients sont traites a l'aide de differents schemas pharmacologiques sans donnees probantes quant aux effets indesirables specifiques a leur sexe. Nous avons vise a etudier les differences entre la frequence des effets indesirables de la chimiotherapie dans le traitement du cancer du pancreas en vue de fournir des elements de reflexion quant a l'aide personnalisee fondee sur des besoins individuels. La population echantillonnee est composee de 207 patients. Le modele de regression a mis en evidence le role predictif du sexe feminin quant a l'alopecie, a la constipation, au syndrome pied-main et aux douleurs epigastriques. Nous avons aussi rapporte des differences entre les sexes selon des schemas therapeutiques individuels. En outre, une evaluation selon l'age a permis de rapporter un decroissement general du risque de toxicite chez les patients jeunes. Nous recommandons de proceder a des etudes medicales et pharmacologiques selon le sexe en vue d'offrir aux patients une chimiotherapie personnalisee et de faire augmenter leur taux de survie de meme que leur qualite de vie pendant le traitement. [Traduit par la Redaction] Mots-cles : differences entre les sexes, effets indesirables, toxicite medicamenteuse, chimiotherapie, cancer du pancreas., 1. Introduction Recent studies demonstrate gender-specific incidence, progression, and severity of different tumors. Differences in parameters such as body weight, fat distribution, hormonal profile, metabolism, immune response, and genetics were [...]

Simple Summary: Sleep is a fundamental human need. Good-quality sleep has a protective role that allows people to carry out daily activities adequately, ensuring well-being. Prolonged wakefulness causes a wide spectrum of disabilities. This study aims to understand the effects of sleep complaints on health and quality of life for cancer patients, and it has been conducted through the creation of questionnaires for patients to investigate the potential alteration of the sleep pattern. The results obtained may serve as the foundation for designing awareness campaigns, providing information, and updating patients, healthcare personnel, and caregivers. It is definitively important, in fact, to begin an evaluation of the negative effects of sleep complaints in the field of cancer. The model developed can also be replicated in different clinical settings: data adjustment by different parameters (i.e., geographic locations, age, sex, and gender) can be the key to improving the patient's quality of life. Sleep is a fundamental human need; sleep disruption, in fact, causes an increase in the activity of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, metabolic effects, changes in circadian rhythms, and pro-inflammatory responses. The scientific literature is finally starting to pay attention to the central role of sleep alterations in patients health. Oxaliplatin is extensively used for the treatment of gastrointestinal cancer and other malignancies, with an increased frequency of use in recent years. This study aims to understand the effects of sleep complaints on health and quality of life in cancer patients treated with oxaliplatin. A study has been conducted through the creation and distribution of questionnaires to patients to investigate their complaints about sleep quality. We observed significant differences between males and females in evaluating sleep hygiene scores, the Pittsburgh Sleep Quality Index, and previous difficulty sleeping. Moreover, in females, stress, worries, and anxiety seem to play a negative role in the sleep hygiene score. The obtained results could improve the interest of healthcare personnel and caregivers in sleep quality in patients undergoing chemotherapy. [ABSTRACT FROM AUTHOR]

Tyrosine kinase inhibitors work by blocking the tyrosine kinases responsible for the dysregulation of intracellular signalling pathways in tumour cells. This study looked at the impact of age and sex on the levels of imatinib, dasatinib, nilotinib, and ponatinib in plasma and cerebrospinal fluid samples of patients with chronic myeloid leukaemia. Imatinib and dasatinib were used to treat the majority of the enrolled patients, and most of them were paediatrics. A total of 82.4% of the patients were men; however, sex-related differences in the drugs' pharmacokinetics were not found. Age and imatinib plasma concentration were found to be inversely correlated. The dasatinib concentrations in plasma were found to be substantially lower than those found in cerebrospinal fluid, particularly in paediatrics. Analysing the obtained data, we can state that therapeutic drug monitoring is a useful method for adjusting a patient's treatment schedule that depends on drug concentrations in biological fluids. The use of therapeutic drug monitoring in conjunction with tyrosine kinase inhibitors for the treatment of chronic myeloid leukaemia is supported by a number of sources of evidence. As a result, as the research develops, the tyrosine kinase inhibitor therapeutic drug monitoring classification needs to be refined in terms of factors like sex and age. [ABSTRACT FROM AUTHOR]